Company / Current Liabilities per Share
Enliven Therapeutics, Inc. Current Liabilities per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$0.34
FY2024
5-year range
$0.33 / $3.11
FY2020-FY2024
Trend
-53.6%
vs FY2023
Sector context
#172 of 210
Health Care
What the data says
Enliven Therapeutics, Inc.'s current liabilities per share of $0.34 is lower than 82% of companies in the Health Care sector (FY2024). Improved from $3.11 to $0.34 over the past 2 years.
Based on SEC 10-K filings.
0.34 in FY2024 with a 5-year CAGR of -43.7%.
Improved from $3.11 to $0.34 over the past 2 years.
Health Care sector context is included.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- +0.5%
- 5-Year CAGR
- -43.7%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 210This company $0.34 Sector average $15.78
▼
-97.9% below sector average
Key checks
Key Insights
- In FY2024, current liabilities per share decreased 53.6% year-over-year.
- Ranks #172 out of 210 companies in the Health Care sector.
- Peak current liabilities per share was recorded in FY2019.
- Lowest current liabilities per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.34 | -53.6% |
| FY2023 | $0.73 | -76.6% |
| FY2022 | $3.11 | +834.2% |
| FY2021 | $0.33 | -25.8% |
| FY2020 | $0.45 | -92.5% |
| FY2019 | $5.98 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026